Sector News

BioNTech announces new facility in Singapore

May 16, 2021
Life sciences

BioNTech has announced that it will build an mRNA manufacturing facility in Singapore as well as establish its regional headquarters for Southeast Asia there.

BioNTech, in partnership with Pfizer, has developed an mRNA Covid-19 vaccine. It is also developing patient-specific cancer immunotherapies. It currently has more than 20 product candidates with ten candidates in ongoing clinical trials.

The new manufacturing facility will be established with support from the Singapore Economic Development Board.

The facility will have highly automated mRNA production capabilities for drug substance, drug product, and fill-and-finish. It will be able to produce a range of mRNA vaccines and therapeutics for infectious diseases and cancer, and will have a production capacity of several hundred million mRNA doses depending on the vaccine. It will provide regional and global supply capacity for BioNTech’s mRNA-based product candidates and will also enable a rapid response for Southeast Asia in any future pandemics.

Construction of the facility will begin this year, subject to planning approval, and could be operational as early as 2023.

Ugur Sahin, CEO and Co-founder of BioNTech, said: “Having multiple nodes in our production network is an important strategic step in building out our global footprint and capabilities. With this planned mRNA production facility, we will increase our overall network capacity and expand our ability to manufacture and deliver our mRNA vaccines and therapies to people around the world.”

Beh Swan Gin, Chairman of Singapore’s Economic Development Board, said: “We strongly welcome BioNTech’s plan to establish its mRNA manufacturing facility and regional headquarters in Singapore. The investment will enable Singapore to develop capabilities in an important new therapeutic modality as part of the strategy to grow our biopharmaceutical industry. In particular, BioNTech’s mRNA manufacturing facility will contribute significantly to the region’s ability to address future pandemic threats.”

by Amanda Doyle

Source: thechemicalengineer.com

Related News

June 13, 2021

Making drug-resistant bacteria susceptible to antibiotics

Life sciences

Antibiotic resistance remains one of the biggest public health challenges. New drugs are still needed to tackle tough-to-treat bacteria. But finding new therapeutics to kill off pathogenic bacteria has been difficult.

June 13, 2021

Vexed by vectors: How COVID-19 vaccine and cell and gene players are tackling the viral vector bottleneck

Life sciences

Viral vectors are engineered viruses used to deliver gene therapies, gene-modified cell therapies and certain vaccines. And their shortage is already upon us, thanks to manufacturing approaches that simply haven’t kept pace with the advance of cell and gene therapies.

June 13, 2021

Beigene expands into cancer cell therapy with Shoreline pact

Life sciences

Beigene, a fast-growing drugmaker based in Cambridge, Massachusetts and Beijing, will partner with Shoreline Biosciences to develop cell therapies for cancer, expanding its research beyond the small molecule and antibody drugs.

Send this to a friend